News articles about Tocagen (NASDAQ:TOCA) have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tocagen earned a news impact score of 0.14 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.5305208560233 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Separately, Zacks Investment Research cut shares of Tocagen from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th.
Tocagen (NASDAQ TOCA) opened at $10.86 on Friday. Tocagen has a 1 year low of $8.60 and a 1 year high of $17.95. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.03 and a quick ratio of 6.03.
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.